J.P. Morgan Downgrades Abbott Labs to 'Neutral'

Analyst Michael Weinstein sees a diminished outlook for growth in 2004 due to potential generic drug competition

J.P. Morgan downgraded Abbott Labs (ABT ) to neutral from overweight.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.